ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Abemaciclib in Recurrent Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02981940
Recruitment Status : Active, not recruiting
First Posted : December 5, 2016
Last Update Posted : March 27, 2018
Sponsor:
Collaborator:
Eli Lilly and Company
Information provided by (Responsible Party):
Eudocia Quant Lee, MD, Dana-Farber Cancer Institute

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : April 2020
  Estimated Study Completion Date : April 2022